Efficacy outcomes with InO or SC by ALL subtype. (A) CR/CRi rates were higher with InO than with SC across leukemic subtypes, with the difference reaching statistical significance in the BCR::ABL1–like subtype. (B) A trend toward benefit with InO was observed across leukemic subtypes for PFS; and (C) across most subtypes for OS. ^aCIs were approximated using nominal distribution when ≥5 patients were in both the CR/CRi and non–CR/CRi subgroups. Where <5 patients were in either subgroup, exact method was used; ^bincluded DUX4, CDX2/UBTF, MEF2D, TCF3::PBX1, and ZNF384; ^cincluded hyperdiploid; ^dincluded B-other, PAX5alt, and ZEB2/CEBP.